CA2587489C - Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci - Google Patents

Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci Download PDF

Info

Publication number
CA2587489C
CA2587489C CA2587489A CA2587489A CA2587489C CA 2587489 C CA2587489 C CA 2587489C CA 2587489 A CA2587489 A CA 2587489A CA 2587489 A CA2587489 A CA 2587489A CA 2587489 C CA2587489 C CA 2587489C
Authority
CA
Canada
Prior art keywords
lower alkyl
hedgehog
substituted
compound
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2587489A
Other languages
English (en)
Other versions
CA2587489A1 (fr
Inventor
Oivin M. Guicherit
Edward Andrew Boyd
Shirley Ann Brunton
Stephen Price
John Harry Alexander Stibbard
Colin H. Mackinnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35825314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2587489(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2587489A1 publication Critical patent/CA2587489A1/fr
Application granted granted Critical
Publication of CA2587489C publication Critical patent/CA2587489C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2587489A 2004-11-03 2005-11-03 Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci Expired - Fee Related CA2587489C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62453604P 2004-11-03 2004-11-03
US60/624,536 2004-11-03
PCT/US2005/040054 WO2006050506A1 (fr) 2004-11-03 2005-11-03 Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci

Publications (2)

Publication Number Publication Date
CA2587489A1 CA2587489A1 (fr) 2006-05-11
CA2587489C true CA2587489C (fr) 2013-12-31

Family

ID=35825314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2587489A Expired - Fee Related CA2587489C (fr) 2004-11-03 2005-11-03 Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci

Country Status (8)

Country Link
US (3) US7816369B2 (fr)
EP (1) EP1807074B1 (fr)
JP (1) JP2008519044A (fr)
AU (1) AU2005301962B2 (fr)
CA (1) CA2587489C (fr)
IL (1) IL182982A (fr)
NZ (1) NZ555419A (fr)
WO (1) WO2006050506A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4658473B2 (ja) 2001-07-27 2011-03-23 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用
EP1807074B1 (fr) * 2004-11-03 2013-10-23 Curis, Inc. Mediateurs de voies de signalisation hedgehog, compositions et utilisations liees a ceux-ci
WO2007036769A1 (fr) * 2005-07-05 2007-04-05 Pfizer Products Inc. Dérivés d’aminothiazole en tant qu'agonistes du récepteur de la thrombopoïétine
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20090258917A1 (en) * 2005-10-12 2009-10-15 Benjamin Pelcman Benzoxazoles Useful in the Treatment of Inflammation
EP1905764A1 (fr) 2006-09-30 2008-04-02 Sanofi-Aventis 2-Phenylbenzimidazoles et leur utilisation comme composés pharmaceutiques
CA2683946C (fr) 2007-04-18 2013-01-22 Merck & Co., Inc. Derives de triazole qui sont des antagonistes de smo
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
KR101143246B1 (ko) * 2007-06-29 2012-05-18 화이자 인코포레이티드 벤즈이미다졸 유도체
UY31322A1 (es) * 2007-09-05 2009-04-30 Amidas heterocíclicas y sus métodos de uso-975
WO2009035568A1 (fr) * 2007-09-07 2009-03-19 Amgen Inc. Pyridazines annelées destinées au traitement de tumeurs induites par une signalisation hedgehog inadaptée
HRP20130992T1 (hr) * 2008-04-29 2013-11-22 Merck Patent Gmbh Derivati arilpirazinona kao stimulatori luäśenja inzulina, postupci za njihovo dobivanje i njihova uporaba za lijeäśenje dijabetesa
WO2010021381A1 (fr) * 2008-08-22 2010-02-25 武田薬品工業株式会社 Dérivé hétérocyclique fusionné et son utilisation
EP2184273A1 (fr) 2008-11-05 2010-05-12 Bayer CropScience AG Composés substitués par l'halogène comme pesticides
EP2376502B1 (fr) 2008-12-19 2015-06-17 GlaxoSmithKline LLC Composés thiazolopyridines de modulation des sirtuines
BRPI1011247A2 (pt) 2009-06-09 2016-06-21 California Capital Equity Llc derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
FR2948367A1 (fr) 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
PL2470173T3 (pl) * 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
CA2772194A1 (fr) * 2009-09-01 2011-03-10 Pfizer Inc. Derives de benzimidazole
TWI617559B (zh) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
TWI574687B (zh) * 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
WO2013059634A1 (fr) * 2011-10-20 2013-04-25 The Regents Of The University Of California Utilisation d'inhibiteurs de cdk9 pour réduire la dégradation cartilagineuse
CN103087045B (zh) * 2013-01-11 2015-08-12 上海交通大学 一种苯并咪唑类杂环化合物、药物组合物及其用途
CN103214456B (zh) * 2013-04-20 2015-02-25 郎恒元 具有抗肿瘤活性的苯并咪唑类化合物、制备方法及其应用
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
WO2015073691A1 (fr) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Procédés pour traiter le cancer par activation de la signalisation bmp
EP3698815B1 (fr) 2014-03-21 2024-02-21 University of Pittsburgh- Of the Commonwealth System of Higher Education Hydrogel stérilisé de manière terminale dérivé d'une matrice extracellulaire
JP6930913B2 (ja) 2014-10-14 2021-09-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法
EP3221309B1 (fr) * 2014-11-20 2019-11-13 Council of Scientific and Industrial Research Nouveaux inhibiteurs de l'egfr à base de benzimidazole
US11406736B2 (en) 2016-01-13 2022-08-09 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Vascular extracellular matrix hydrogel
WO2018121610A1 (fr) * 2016-12-27 2018-07-05 山东大学 Inhibiteur de la voie hedgehog pour souche smoothened mutante
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론
CN114790177B (zh) * 2021-01-26 2024-03-26 首都医科大学附属北京天坛医院 新型Hedgehog信号通路抑制剂
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN114907358A (zh) * 2021-02-09 2022-08-16 上海翰森生物医药科技有限公司 含吡啶多环类衍生物调节剂、其制备方法和应用
CN113461063B (zh) * 2021-06-29 2022-10-25 哈尔滨工业大学 一种二氧化锰纳米酶的制备方法及其应用
WO2025151620A1 (fr) * 2024-01-10 2025-07-17 The Children's Medical Center Corporation Composés d'imidazopyrimidine fonctionnalisés et leurs utilisations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826912B1 (fr) 2001-07-09 2004-01-30 Valeo Climatisation Installation de chauffage d'habitacle de vehicule automobile
JP4658473B2 (ja) * 2001-07-27 2011-03-23 キュリス，インコーポレイテッド ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
SE525183C2 (sv) 2002-04-04 2004-12-21 Xelerated Ab Förfarande och medel för behandling med pipelining av datapaket
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1807074B1 (fr) * 2004-11-03 2013-10-23 Curis, Inc. Mediateurs de voies de signalisation hedgehog, compositions et utilisations liees a ceux-ci

Also Published As

Publication number Publication date
AU2005301962B2 (en) 2011-10-20
US20090012082A1 (en) 2009-01-08
US20100317660A1 (en) 2010-12-16
JP2008519044A (ja) 2008-06-05
EP1807074B1 (fr) 2013-10-23
US8168653B2 (en) 2012-05-01
NZ555419A (en) 2009-07-31
IL182982A0 (en) 2007-08-19
EP1807074A1 (fr) 2007-07-18
IL182982A (en) 2013-02-28
US7816369B2 (en) 2010-10-19
US8815895B2 (en) 2014-08-26
WO2006050506A1 (fr) 2006-05-11
CA2587489A1 (fr) 2006-05-11
US20120283258A1 (en) 2012-11-08
AU2005301962A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
CA2587489C (fr) Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci
AU2002327390B2 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2003231032B2 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU780612B2 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
US9173869B2 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2002327390A1 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2005507860A5 (fr)
AU2849100A (en) Regulators of the PCT or smoothened pathway, compositions and uses related thereto
ZA200400582B (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto.
AU2011224045A1 (en) Modulators of hedgehog signaling pathways, compositions and uses related thereto

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171103